The new generation weight-loss drug developed by the U.S. biotechnology company Metsera, Inc. (MTSR) demonstrated excellent ...

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) reported a rise in third-quarter revenue and earnings but surprised ...

Novo Nordisk A/S has again increased its offer for Metsera Inc. as its takeover battle with Pfizer Inc. for the obesity ...

Pfizer and Novo Nordisk are engaged in an intense bidding war for Metsera, a biotech company known for developing obesity drugs. Novo has raised its offer above Pfizer's $10 billion bid, escalating ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its ...

Pfizer and Novo Nordisk’s bidding war for the weight loss drugmaker Metsera is intensifying. Five updates: 1. Pfizer matched Novo Nordisk’s $10 billion bid for the biotech firm Nov. 5, one day after ...

The battle for obesity drug maker Metsera has escalated into a high-stakes bidding war between two pharmaceutical giants, ...

A heated bidding war has erupted between Novo Nordisk and Pfizer over U.S. biotech firm Metsera and its obesity drug assets, valued at $10 billion. Novo's higher offer has stirred tensions, with ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer.

A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 ...